U.S., Oct. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07217496) titled 'N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer' on Oct. 14.
Brief Summary: This phase Ib trial will investigate the effect of N-803 in combination with pembrolizumab and enfortumab vedotin in treating participants with urothelial cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic).
Study Start Date: Nov. 30
Study Type: INTERVENTIONAL
Condition:
Metastatic Urothelial Carcinoma
Urothelial Carcinoma
Locally Advanced Urothelial Carcinoma
Urothelial Cancer
Int...